Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02118337
Title A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

Advanced Solid Tumor

Therapies

Durvalumab + MEDI0680

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.